Use of sofosbuvir in chronic kidney disease: Is it necessary?
Tae Seop Lim, Sang Hoon Ahn
Clin Mol Hepatol. 2017;23(4):308-310. Published online 2017 Sep 26 DOI: https://doi.org/10.3350/cmh.2017.0109
Citations to this article as recorded by 
Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir
Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar
Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 82. CrossRef
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment
Mark Sulkowski, Laura E. Telep, Massimo Colombo, Francois Durand, K. Rajender Reddy, Eric Lawitz, Marc Bourlière, Nelson Cheinquer, Stacey Scherbakovsky, Liyun Ni, Lindsey Force, Heribert Ramroth, Anuj Gaggar, Anand P. Chokkalingam, Meghan E. Sise
Alimentary Pharmacology & Therapeutics.2022; 55(9): 1169. CrossRef
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa
Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1. CrossRef
An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy
Guglielmo Borgia, Riccardo Scotto, Antonio Riccardo Buonomo
Expert Opinion on Investigational Drugs.2019; 28(5): 395. CrossRef
Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection
Riccardo Scotto, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Alberto Enrico Maraolo, Emanuela Zappulo, Biagio Pinchera, Ivan Gentile, Guglielmo Borgia
Reviews on Recent Clinical Trials.2019; 14(3): 173. CrossRef
Lamivudine: fading into the mists of time
Jonggi Choi, Young-Suk Lim
Clinical and Molecular Hepatology.2017; 23(4): 314. CrossRef